AON Partnered With Payers to Reduce Prior Authorization
A new trust-based model aims to streamline oncology care by using performance data to bypass standard insurance hurdles.
Updated on Oct. 2, 2026 in Cancer
Live Poll
Should data-sharing between oncology providers and insurance companies be used to reduce patient authorization requirements?
AON has collaborated with Evolent Health and a major payer to analyze physician utilization and care quality. This initiative seeks to replace rigid prior authorization requirements with a trust model based on consistent evidence-based practice.
Why it matters
Prior authorization can delay access to life-saving cancer care, and this model uses proven clinical data to remove those administrative barriers. The partnership aims to build a framework where oncology practices are evaluated on outcomes rather than individual service approvals.
AON utilized data from the COA Quality and Value Study conducted with Flatiron Health to validate its care quality. This approach centers on tracking specific ordering patterns and adherence to evidence-based pathways versus existing insurance industry standards.
The players
AON
An oncology network that facilitates access to advanced cancer treatments like CAR-T therapy and bispecifics in rural and underserved regions.
Evolent Health
A health technology company that partners with providers and payers to improve care delivery and manage patient outcomes.
Flatiron Health
A health tech firm specializing in oncology data and analytics that helped facilitate the COA Quality and Value Study.
The details
The collaboration evaluates physician utilization patterns and adherence to established clinical pathways to create a value-based trust pool. By proving that treatment decisions align with high-quality outcomes, the system aims to automate approval for complex cancer treatments. AON specifically leverages this framework to manage the delivery of chimeric antigen receptor T-cell therapy, bispecific therapy, and radioligand therapy in rural areas.
Timeline
October 2026: The partnership model was established.
Health Landscape
This initiative signals a shift in oncology toward data-driven quality assessments that aim to bypass traditional administrative gatekeeping. It marks a departure from standard, transaction-by-transaction insurance verification by aligning physician performance with clinical pathways.
If you receive cancer treatment through an AON provider, this model may eventually lead to faster approval for advanced therapies like radioligand treatments. Patients should consult their oncologist to understand how their specific care team tracks performance metrics and if their treatment plan qualifies for these streamlined pathways.
The takeaway
The move toward trust-based oncology care relies on data transparency to ensure patient access is not interrupted by administrative delays. Discussing your care pathway with your oncologist can provide clarity on how your practice manages insurance approvals and clinical quality standards.
Further reading
For broader trends in treatment access, see the latest developments in Cancer.
Source note: This article includes information reported by Ajmc.
Live Poll
Should data-sharing between oncology providers and insurance companies be used to reduce patient authorization requirements?
